Ítem


Familial dilated cardiomyopathy: a multidisciplinary entity, from basic screening to novel circulating biomarkers

Idiopathic dilated cardiomyopathy has become one of the most prevalent inherited cardiomyopathies over the past decades. Genetic screening of first-degree relatives has revealed that 30-50% of the cases have a familial origin. Similar to other heart diseases, familial dilated cardiomyopathy is characterized by a high genetic heterogeneity that complicates family studies. Cli’nical screening, 12-lead electrocardiogram and transthoracic echocardiogram are recommended for patients and first-degree family members. Magnetic resonance also needs to be considered. Genetic technologies have become fundamental for the clinical management of this disease. New generation sequencing methods have made genetic testing feasible for extensive panels of genes related to the disease. Recently, new imaging modalities such as speckle-tracking, strain and strain rate or magnetic resonance, and circulating biomarkers such as non-coding RNAs, have emerged as potential strategies to help cardiologists in their clinical practice. Imaging, genetic and blood-based techniques should be considered together in the evaluation and testing of familial dilated cardiomyopathy. Here, we discuss the current procedures and novel approaches for the clinical management of familial dilated cardiomyopathy

Elsevier

Autor: de Gonzalo-Calvo D
Quezada M
Campuzano Larrea, Oscar
Perez-Serra, Alexandra
Broncano J
Ayala R
Ramos M
Llorente-Cortes V
Blasco-Turrión S
Morales FJ
Gonzalez P
Brugada, Ramon
Mangas A
Toro R
Data: 1 febrer 2017
Resum: Idiopathic dilated cardiomyopathy has become one of the most prevalent inherited cardiomyopathies over the past decades. Genetic screening of first-degree relatives has revealed that 30-50% of the cases have a familial origin. Similar to other heart diseases, familial dilated cardiomyopathy is characterized by a high genetic heterogeneity that complicates family studies. Cli’nical screening, 12-lead electrocardiogram and transthoracic echocardiogram are recommended for patients and first-degree family members. Magnetic resonance also needs to be considered. Genetic technologies have become fundamental for the clinical management of this disease. New generation sequencing methods have made genetic testing feasible for extensive panels of genes related to the disease. Recently, new imaging modalities such as speckle-tracking, strain and strain rate or magnetic resonance, and circulating biomarkers such as non-coding RNAs, have emerged as potential strategies to help cardiologists in their clinical practice. Imaging, genetic and blood-based techniques should be considered together in the evaluation and testing of familial dilated cardiomyopathy. Here, we discuss the current procedures and novel approaches for the clinical management of familial dilated cardiomyopathy
Format: application/pdf
Accés al document: http://hdl.handle.net/10256/24313
Llenguatge: eng
Editor: Elsevier
Col·lecció: info:eu-repo/semantics/altIdentifier/doi/10.1016/j.ijcard.2016.11.045
info:eu-repo/semantics/altIdentifier/issn/0167-5273
info:eu-repo/semantics/altIdentifier/eissn/1874-1754
Drets: Tots els drets reservats
Matèria: Marcadors bioquímics
Biochemical markers
Ressonància magnètica
Magnetic resonance
Miocardi--Malalties
Myocardium--Diseases
Genètica
Genetics
Ecocardiografia
Echocardiography
RNA
Cardiopatia congènita
Congenital heart disease
Títol: Familial dilated cardiomyopathy: a multidisciplinary entity, from basic screening to novel circulating biomarkers
Tipus: info:eu-repo/semantics/article
Repositori: DUGiDocs

Matèries

Autors